News & Updates

Show Multimedia Only
Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity
Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity
17 Sep 2025 byStephen Padilla

Patients with heart failure (HF) with preserved ejection fraction (HFpEF), obesity, and type 2 diabetes (T2D) show a favourable response to tirzepatide despite less pronounced weight loss, reports a study.

Diabetes does not influence effects of tirzepatide in HFpEF patients with obesity
17 Sep 2025